Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityConvertible DebtCurrent AssetsCurrent Deferred RevenueCurrent LeasesLiabilities and Shareholders EquityLong-Term InvestmentsNon-Current AssetsNon-Current DebtOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesReceivables - NetRetained EarningsShareholder's EquityShort term DebtShort-term InvestmentsTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Cytokinetics (CYTK) Total Non-Current Liabilities: 2016-2025

Historic Total Non-Current Liabilities for Cytokinetics (CYTK) over the last 8 years, with Sep 2025 value amounting to $2.0 billion.

  • Cytokinetics' Total Non-Current Liabilities was N/A to $2.0 billion in Q3 2025 from the same period last year, while for Sep 2025 it was $2.0 billion, marking a year-over-year change of. This contributed to the annual value of $1.2 billion for FY2023, which is 7.92% up from last year.
  • According to the latest figures from Q3 2025, Cytokinetics' Total Non-Current Liabilities is $2.0 billion, which was up 22.84% from $1.6 billion recorded in Q2 2025.
  • Cytokinetics' Total Non-Current Liabilities' 5-year high stood at $2.0 billion during Q3 2025, with a 5-year trough of $340.3 million in Q1 2021.
  • For the 3-year period, Cytokinetics' Total Non-Current Liabilities averaged around $1.4 billion, with its median value being $1.2 billion (2023).
  • Data for Cytokinetics' Total Non-Current Liabilities shows a peak YoY skyrocketed of 170.16% (in 2022) over the last 5 years.
  • Over the past 5 years, Cytokinetics' Total Non-Current Liabilities (Quarterly) stood at $593.0 million in 2021, then spiked by 89.15% to $1.1 billion in 2022, then rose by 7.92% to $1.2 billion in 2023, then rose by 7.71% to $1.2 billion in 2024, then increased by 26.86% to $2.0 billion in 2025.
  • Its Total Non-Current Liabilities stands at $2.0 billion for Q3 2025, versus $1.6 billion for Q2 2025 and $1.5 billion for Q1 2025.